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Abstract
Poly(lactic-co-glycolic acid) (PLGA) nanoparticles were studied as drug delivery vehicles for calcitriol, the active form of vitamin
D3. In vitro effects of calcitriol encapsulated in PLGA nanoparticles were evaluated with respect to free calcitriol on human pancre-
atic cell lines, S2-013 and hTERT-HPNE, and the lung cancer cell line A549. Encapsulated calcitriol retained its biological activity,
reducing the cell growth. Cytotoxicity assays demonstrated that encapsulation of calcitriol enhanced its inhibitory effect on cell
growth at a concentration of 2.4 μM for the S2-013 cells (91%) and for A549 cells (70%) comparared to the free calcitriol results.
At this concentration the inhibitory effect on nontumor cells (hTERT-HPNE) decreased to 65%. This study highlights the ability of
PLGA nanoparticles to deliver vitamin D3 into cancer cells, with major effects regarding cancer cell cycle arrest and major changes
in the cell morphological features.
Introduction
Vitamin D3, a secosteroid hormone produced through sunlight
exposure [1], can be found with different chemical structures:
calciol or cholecalciferol, calcidiol and calcitriol. Cholecalcif-
erol is inert and must be metabolized in the liver and the kidney
through two hydroxylation processes in order to be converted
into its active form, calcitriol [2]. Calcitriol acts like classical
steroid hormones, binding to vitamin D receptor (VDR) and
targeting gene expression via both genomic and nongenomic
pathways [1]. Although known as an important regulator of
calcium homeostasis and bone mineralization [3], several
studies support that vitamin D also plays a major role in tumor
pathogenesis, progression and therapy [2]. Calcitriol is also
regarded as a cancer chemopreventive agent due to promising
epidemiological, preclinical and clinical findings [4]. The
protective role of vitamin D against cancer has been mainly
attributed to its anti-inflammatory activity [5].
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The antineoplastic activity of calcitriol in pancreatic and lung
cancer is well established, as reported by various in vitro and in
vivo studies [6-13]. Several pathways by which calcitriol may
prevent, treat or stop tumor growth have been described [1,2].
However, calcitriol exhibits antitumoral activity only in supra-
physiological doses associated with a high risk of hypercal-
cemia [14]. Also, vitamin D3 is sensitive to many external and
environmental factors such as temperature changes, oxygen
pressure, light, etc. that may affect the molecular structure and
the associated functionality [15]. Studies also show that more
than 75% of vitamin D intake is catabolized and excreted before
being converted to its active form or before its storage. In addi-
tion to these drawbacks, the clinical use of vitamin D3 exhibits
other concerns as its short half-life in the bloodstream [16] and
first-pass effect [17].
Despite multiple the medicinal benefits of calcitriol, the
discussed drawbacks continue to be highlighted as major chal-
lenges in developing formulations for clinical use. To over-
come some of these limitations, we propose drug delivery
systems for new calcitriol formulations. These nanosystems,
namely nanoparticles (NPs), must meet several requirements
such as biocompatibility, biodegradability, mechanical strength,
FDA approval and low synthesis complexity. One of the most
attractive candidates is poly(lactic-co-glycolic acid) (PLGA),
which is a copolymer of poly(lactic acid) (PLA) and
poly(glycolic acid) (PGA) [18,19]. We expect that vitamin D3
encapsulation in these polymeric NPs will increase bioavail-
ability by preventing drug degradation before administration,
increasing the half-life of vitamin D3 in the bloodstream,
avoiding the first-pass effect and circumventing the multidrug
resistance (MDR) problem [18]. Also it is well documented that
PLGA NPs are efficiently internalized by targeted cells,
increasing intracellular drug delivery [20], allowing a sustained
and controlled drug release over time [19]. Moreover, PLGA
NPs could offer selective drug delivery to tumor tissue either by
passive targeting with the enhanced permeability and retention
effect (EPR) [18] or by active targeting, using functionalized
NPs [21]. Thus, the drug toxicity on healthy cells could be
reduced, increasing NPs accumulation in the target tissues [19].
Although several studies on vitamin D3 encapsulation for food
fortification have been conducted, very few works reported the
use of nanocarriers for vitamin D3 delivery towards cancer
treatment. Vitamin D3 vectorisation to guarantee specific action
on malignant cells that avoids side effects such as hypercal-
cemia has been proposed. Nguyen et al. developed a formula-
tion based on poly(vinyl neodecanoate-crosslinked-ethylene-
glycol dimethacrylate) microspheres with a size of about 35 μm
[22]. In this project, the authors used cholecalciferol as a drug
model for calcitriol. They demonstrated that their cholecalcif-
erol-loaded microspheres are biocompatible, allowed for
controlled and sustained release, and increased the efficiency of
the therapy [22]. A few years later, Almouazen et al. developed
a formulation using PLA nanoparticles of about 200 nm [14].
This study proved that PLA nanocapsules are a suitable choice
for controlled delivery of antineoplastic agents, namely the
nanoencapsulated calcidiol induced a significant growth inhibi-
tion when compared to free calcidiol, and the PLA NPs
enhanced the intracellular delivery of vitamin in breast cancer
cells [14]. In another work, Bonor et al. [23] developed
calcitriol-conjugated quantum dots to analyze calcitriol distribu-
tion and dynamics in mouse myoblast cells. The authors
concluded that the designed tool is suitable for imaging
drug–tumor interactions and to deliver drugs to tumors and
metastasized sites [23].
The aim of the present study was to evaluate the capacity of
PLGA NPs to encapsulate and to deliver calcitriol, the active
form of vitamin D3, into human cells. PLGA NPs were prepared
as nanocarriers, and for the purpose of formulating and charac-
terizing the designed system, the inactive form of vitamin D3,
cholecalciferol, was also used as drug model along with
calcitriol. We evaluated the effect of calcitriol-loaded PLGA
NPs on normal and tumor cells in terms of cell growth, cell
cycle arrest and morphological changes.
Results
Nanoparticle physicochemical properties
PLGA NPs were prepared by a single emulsion solvent evapor-
ation method and stabilized with Pluronic®F127. The obtained
results for mean the diameter, polydispersity index (PDI) and
zeta potential for the unloaded PLGA NPs are shown in
Table 1. According to the literature, the PLGA NPs size is
found to be in the range of 100 to 250 nm [20]. The prepared
unloaded NPs are within the expected range, exhibiting a mean
diameter of 172 ± 4 nm, and presenting a zeta potential value of
−38 mV: negative, as expected, due to their carboxylic end
groups (Table 1).
The single emulsion solvent evaporation method allowed the
encapsulation of vitamin D3 in the PLGA NPs. The obtained
results for the mean diameter, PDI, zeta potential, encapsula-
tion efficiency and loading capacity values for the PLGA NPs
loaded with cholecalciferol and calcitriol are also shown in
Table 1. The size of the vitamin-loaded NPs (187 ± 7 nm for
cholecalciferol-loaded, and 186 ± 3 nm for calcitriol-loaded)
increased significantly (p < 0.05) in comparison to unloaded
PLGA NPs (172 ± 4 nm). Moreover, the mean size values were
not significantly different between cholecalciferol and
calcitriol-loaded NPs (p > 0.05). The prepared systems exhib-
ited a narrow size distribution (PDI ≤ 0.1). TEM analysis
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Table 1: Physicochemical features of unloaded, cholecalciferol and calcitriol-loaded PLGA NPs. The data is presented as the mean ± SD (n = 3).
PLGA NPs Mean diameter (nm) PDI Zeta potential (mV) EE (%) LC (%)
Unloaded 172 ± 4 0.064 ± 0.040 −38 ± 3 – –
Cholecalciferol-loaded 187 ± 7 0.110 ± 0.065 −29 ± 3 83 ± 2 8.3 ± 0.2
Calcitriol-loaded 186 ± 3 0.056 ± 0.025 −34 ± 4 57 ± 8 5.7 ± 0.9
Figure 1: TEM images of (a) unloaded PLGA nanospheres, scale bar: 200 nm; and (b) loaded PLGA nanospheres, scale bar: 500 nm. The white
arrow indicates the pluronic layer surrounding the PLGA NP.
Table 2: PLGA NPs physicochemical characterization after freeze-drying experiments, with and without a cryoprotective agent. The mean size varia-
tion is expressed in terms of the ratio d/d0, where d is mean diameter after freeze-drying and d0 is the initial NP mean diameter. The data is presented
as the mean ± SD (n = 3).
Calcitriol–PLGA NPs Mean diameter (nm) d/d0 PDI Zeta potential (mV)
Before freeze-drying 186 ± 3 – 0.056 ± 0.025 −34 ± 4
After freeze-drying
Without cryoprotection 1591 ± 167 8.55 0.613 ± 0.370 −31 ± 1
Sucrose 1% 193 ± 1 1.04 0.096 ± 0.028 −29 ± 3
revealed spherical- and uniform-shaped PLGA nanoparticles, as
shown in Figure 1. The diameter of the nanoparticles revealed
by this method varies between approximately 170 and 190 nm,
which is consistent with the size measurements by DLS.
The absolute value of the zeta potential significantly decreased
from 38 in unloaded PLGA NPs to 29 in cholecalciferol-loaded
NPs (p < 0.05). The decrease to 34 mV observed for calcitriol-
loaded NPs was not significant (p > 0.05). Moreover, zeta
potential values were not significantly different between chole-
calciferol and calcitriol-loaded NPs (p > 0.05).
The obtained results for the encapsulation efficiency (EE) for
both encapsulated forms of vitamin D3 are presented in Table 1.
The attained values significantly decrease (p < 0.05) from
83 ± 2% for cholecalciferol to 57 ± 8% for calcitriol. The
loading capacity of PLGA NPs was also evaluated, exhibiting
significant differences in the determined values (p < 0.05) of
8.3 ± 0.2% for cholecalciferol-loaded NPs and 5.7 ± 0.9% for
the NPs loaded with calcitriol (Table 1). The yield of the PLGA
NPs production process reached values of 57 ± 4% (n = 3).
Calcitriol-loaded PLGA nanoparticles stability studies were
carried out at 4 °C over 60 days. The NPs showed a mean size
of 186 ± 3 nm, which remained constant over time, exhibiting a
mean d/d0 value of 1.0 for approximately 50 days. The d/d0
parameter refers to the ratio between mean diameter at each set
time measurement during the 50 days and the initial NP mean
diameter. After this period, the d/d0 ratio increased to 6.4.
The obtained results for the mean diameter, PDI and zeta poten-
tial, presented in Table 2, allowed for the assessment of aggre-
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gation or modification of the PLGA NPs properties after freeze-
drying.
The NP PDI values and mean diameter significantly increased
from 186 ± 3 nm to 1591 ± 167 nm (p < 0.05) after lyophiliza-
tion without the cryoprotectant agent (Table 2), showing that
the freeze-drying process caused PLGA NP aggregation,
resulting in high polydispersity. No significant changes
(p > 0.05) were observed for the zeta potential values. Hence, it
is possible to conclude that these PLGA NPs are not able to
overcome the stress caused by the lyophilization process,
leading to their destabilization and further aggregation.
However, these results also demonstrated that 1% w/v sucrose
preserves particle integrity after reconstitution of lyophilized
PLGA nanoparticles, yielding no significant changes in the
mean diameter (p > 0.05). However, the zeta potential values
suffer a decrease in the presence of sucrose (p > 0.05). This
could be explained by sucrose adsorption on the NPs surface.
Calcitriol release from the PLGA nanoparticle
The release of calcitriol entrapped in PLGA NPs was carried
out in PBS (0.01 M, pH 7.4 at 37 °C) and the results are
presented in Figure 2.
Figure 2: In vitro release profile of calcitriol from PLGA NPs in PBS
(0.01 M, pH 7.4) at 37 °C. The data is represented as the mean ± SD
(n = 3).
The prepared PLGA NPs exhibited an initial rapid release, fol-
lowed by a slower, sustained release. As Figure 2 shows,
calcitriol released at 24 h was around 46%. This initial rapid
release might be attributed to the release of the surface-
adsorbed vitamin. The calcitriol entrapped in the polymeric
matrix of the NP was released later and in a more controlled
manner, reaching a quasi-plateau between 96 and 168 h. The
plateau represented a release of about 4% of the encapsulated
calcitriol in this period. After 168 h, the total calcitriol released
was around 80%. The control sample showed that calcitriol
remained stable at release conditions throughout the experi-
ment period.
Cellular uptake of PLGA NPs and calcitriol-
induced morphological changes
The internalization of fluorescent C6–calcitriol–PLGA NPs by
S2-013, hTERT-HPNE and A549 cells was evaluated by
confocal microscopy. Counterstaining of the cell nuclei was
performed with DAPI and the acidic compartments (including
endosomes and lysosomes) with LysoTrackerTM Red. The
obtained images are presented in Figure 3.
As seen in Figure 3A,D, nontreated pancreatic cells exhibit an
intense green color that masks the red color of the lysotracker
for lysosomes, despite not having been treated with C6. This
fact is justified because both cell lines exhibited autofluores-
cence in the same emission spectrum as C6 and lysotracker.
Lung carcinoma cells did not exhibit this intense autofluores-
cence, therefore allowing the visualization of the NP uptake
(Figure 3G). As shown in Figure 3H, after 2 h of incubation, the
nanoparticles were internalized by A549 cells. It is also possible
to observe some colocalization of C6-PLGA NPs with the red-
stained late endosomes or lysosomes (yellow color, in
Figure 3H). Quantitative analysis with the ImageJ JACoP
“colocalization finder” plug-in was used for colocalization
assessment of the NPs with LysoTracker Red in the lysosomes
of A549 cells [24]. The statistical method provides the Pearson
coefficient (r), which varies between −1 (anti-colocalization)
and +1 (total colocalization) and reflects the unambiguous colo-
calization of two fluorescent probes [25]. The Pearson correla-
tion coefficient for A549 cells significantly decreased from
0.7 ± 0.1 for a 2 h treatment to 0.4 ± 0.1 and 0.14 ± 0.06 for
48 h and 72 h treatment, respectively (p < 0.05). This decrease
over time suggests an endo-lysosomal escape, with most of the
PLGA NPs localized in the cytoplasm after 72 h, as exhibited in
Figure 3I. Due to the intense cell autofluorescence, it was not
possible to determine the Pearson coefficient for both pancre-
atic cell lines. However it was possible to observe yellow dots
in the S2-013 and hTERT-HPNE cells incubated with
C6–calcitriol–PLGA NPs for 2 h (Figure 3B,E). We were able
to observe this colocalization due to the higher green fluores-
cence intensity of C6–calcitriol–PLGA NPs. The presence of
these yellow dots is reduced in cells incubated with
C6–calcitriol–PLGA NPs for 72 h (Figure 3C,F), due to the
endo-lysosomal escape, with most of the PLGA NPs localized
in the cytoplasm. However, it is not possible to distinguish this
due to autofluorescence in the pancreatic cells and extensive
morphological changes. As can be seen in Figure 3C,F, pancre-
atic cells treated with calcitriol–PLGA NPs at 2.4 µM for 72 h
displayed major changes in shape when compared to untreated
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Figure 3: Confocal laser scanning microscopy images of human cells treated with calcitriol entrapped in C6-PLGA NPs. S2-013 cells: (A) control
cells; cells after (B) 2 and (C) 72 h of incubation with C6–calcitriol–PLGA NPs. hTERT-HPNE cells: (D) control cells; cells after (E) 2 and (F) 72 h of
incubation with C6–calcitriol–PLGA NPs. A549 cells: (G) control cells; cells after (H) 2 and (I) 72 h of incubation with C6–calcitriol–PLGA NPs. The
blue color represents the nuclei and the yellow color represents the colocalization of PLGA NPs with the late endosomes/lysosomes. Scale bar:
10 µm for images A–F, and 25 µm from G–I.
growing cells (Figure 3A,D). In contrast, the control cells
display rounded shapes, and the treated cells exhibited enlarged
and flattened irregular shapes and multiple or enlarged nuclei,
in both cell lines. The observed morphological features are
consistent with senescence phenomena.
Cell growth inhibition by calcitriol-loaded NPs
The in vitro cytotoxic effects on three different human cell
lines, hTERT-HPNE, S2-013 and A549, after treatment with
calcitriol entrapped into the PLGA NPs were assessed relative
to free calcitriol in terms of cell growth. Treatment with 0.1%
ethanol and unloaded PLGA NPs during 72 h had no signifi-
cant effect on the cell growth for the used cell lines (data not
showed). These results prove that PLGA nanoparticles are
biocompatible.
The effect of calcitriol at concentrations from 0.005 to 3.2 µM
was tested with concentrations of PLGA in the range of
0.1 µg mL−1 to 50 µg mL−1. The efficacy of calcitriol-loaded
NPs in comparison to free calcitriol was also evaluated. Due to
its known short half-life in the cell culture medium, an assay
with S2-013 cells was performed for 48 h to compare cell
survival between single-addition and daily-renewed calcitriol.
As shown in Figure 4A, the poor stability of calcitriol is re-
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Figure 4: Effects of calcitriol after 48 h treatment on S2-013 cell survival, determined by SRB assay. (A) Comparison between a single-addition and
daily renewal of calcitriol; (B) Comparison between calcitriol free (single-addition) and entrapped in PLGA NPs. Free calcitriol, added only at t = 0, is
represented with triangles and a dotted line; free calcitriol, added at t = 0 and t = 24 h, is represented with squares and a solid line; and calcitriol–NPs
with spheres and a solid line.
Figure 5: Cytotoxic effects of calcitriol free and calcitriol entrapped in PLGA NPs after 48 h (A–C) and 72 h (D–F) treatment on the cell growth of three
human cell lines, (A,D) S2-013, (B,E) hTERT-HPNE and (C,F) A549, determined by a SRB assay. Free calcitriol is represented with squares and a
dotted line; and calcitriol–NPs with spheres and a solid line.
flected by reduced toxicity when cells are treated with a single
addition for 48 h. For the same range of concentrations, single-
added calcitriol at t = 0 shows a decreased in vitro antitumor
activity when compared to daily-renewed calcitriol, resulting in
significantly different (p < 0.05) 48 h IC50 values of 2.19 µM
and 1.51 µM, respectively. Thus, all cytotoxicity assays with
free calcitriol compared to calcitriol-loaded NPs were renewed
daily.
Both free and encapsulated calcitriol exhibited a concentration-
related decrease in cell growth and survival of the human cell
lines (Figure 5, Supporting Information File 1, respectively).
We observed an advantage of PLGA NPs, in that calcitriol–NPs
are more efficient than free calcitriol with regards to cell growth
inhibition (Figure 5). For instance, incubation for 72 h with
3.2 µM nanoencapsulated calcitriol reduced the cell growth of
lung carcinoma cells to about 20% compared to 45% when free
calcitriol was administered (Figure 5F). Thus, drug delivery
with this polymeric system improves calcitriol antiproliferative
activity, resulting in significantly (p < 0.05) lower GI50 values
(Table 3). In a 48 h assay, free calcitriol inhibits the S2-013 cell
growth by 50% when its concentration is 0.78 µM (renewed
daily, total of 2 administrations), which is higher than equiva-
lent 0.53 µM calcitriol of the loaded NPs (added only at t = 0)
with the same effect (Table 3).
Still, it is important to highlight that due to the short calcitriol
half-life in the cell culture medium, the presented free drug
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Table 3: Cytotoxic effects of calcitriol on the growth of cell lines, S2-013, hTERT-HPNE and A549, respectively. The results are expressed as GI50
(the concentration necessary to inhibit cell growth to 50%) at 48 and 72 h of exposure with free calcitriol and entrapped calcitriol in PLGA NPs by SRB
assay.
GI50 (µM)
S2-013 hTERT-HPNE A549
48 h assay
Calcitriol (renewed daily) 0.78 ± 0.01 1.25 ± 0.01 2.04 ± 0.18
Calcitriol–PLGA NPs 0.53 ± 0.02 1.12 ± 0.04 1.03 ± 0.16
72 h assay
Calcitriol (renewed daily) 0.48 ± 0.01 1.08 ± 0.01 1.90 ± 0.25
Calcitriol–PLGA NPs 0.43 ± 0.01 0.83 ± 0.02 0.49 ± 0.10
Figure 6: Cell cycle distribution of S2-013, hTERT-HPNE and A549 cells treated for 72 h with free calcitriol and calcitriol entrapped in PLGA NPs. The
graphs show the percentage of cells in (A) G0/G1, (B) S and (Cc) G2/M phases. The data is represented as the mean ± SD (n = 3).
concentrations were added daily, unlike entrapped calcitriol,
which was loaded in the NPs only once at time t = 0. Thus,
despite that the NPs themselves already show an advantage
compared to free, daily renovated calcitriol, if the comparison
was made between loaded NPs and single-addition, free
calcitriol, that advantage would be much more evident as
demonstrated by Figure 4B.
For the different cell types, treatment with encapsulated
calcitriol for 72 h showed significantly more deleterious effects
than 48 h treatment, resulting in lower GI50 values for the 72 h
assay (p < 0.05) (Table 3). Also, it is quite relevant to analyze
and compare the effect of free calcitriol and loaded NPs on the
different cell lines. The results shown in Figure 5 demonstrated
that the deleterious calcitriol effect was significantly (p < 0.05)
higher in the pancreatic cancer cell line, S2-013. GI50 values for
S2-013 cells are significantly lower than for hTERT-HPNE and
A549 cells (Table 3) (p < 0.05). Although the NPs show poten-
tial for the drug’s effect on the hTERT-HPNE cell line, like-
wise as for the pancreatic tumor cells, hTERT-HPNE cells show
more resistance to the vitamin’s toxicity, whether calcitriol is
encapsulated or not. For instance, while 0.005 µM calcitriol
loaded in PLGA NPs reduced the cell growth of the S2-013 cell
line to about 80% after 48 h, at the same concentration,
calcitriol–PLGA NPs do not show toxicity in the hTERT-HPNE
cell line (Figure 5A,B). The lung carcinoma cell line exhibited
the lowest sensitivity to the free calcitriol’s antiproliferative
activity among the used cell lines (p < 0.05). However, this was
not true for the encapsulated form of calcitriol. This was the cell
line where the encapsulation of calcitriol in NPs proved to be
more advantageous.
Cell cycle arrest by calcitriol-loaded PLGA
NPs
To assess whether the cytotoxic effects of calcitriol are due to
cell cycle inhibition, cell cycle analysis by flow cytometry was
performed in propidium iodide (PI)-stained S2-013, hTERT-
HPNE and A549 cells after treatment with free calcitriol and
calcitriol-loaded PLGA NPs at 1.2 µM for 72 h. PI counter-
staining was used for DNA quantification. The differences in
the DNA content between the cell population allowed the cell
cycle distribution to be studied [26]. The attained results are
presented in Figure 6.
As Figure 6A shows, cell cycle analysis demonstrated a signifi-
cant accumulation of both pancreatic cell lines in the G0/G1
phase after exposure to calcitriol (p < 0.05). This accumulation
was associated to a concomitant decrease in the S or/and G2/M
phases (Figure 6B,C). Additionally, the observed changes on
the cell cycle distribution between control A549 cells and A549
cells treated with free calcitriol for 72 h were not significant
(p > 0.05). These results are in agreement with the proliferation
studies, where the A549 cell line exhibited the lowest sensi-
tivity to the calcitriol antiproliferative effect. As it is also shown
in Figure 6A, encapsulation of calcitriol in PLGA NPs
enhanced the calcitriol growth inhibition, inducing a signifi-
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cantly increased accumulation of cells in the G0/G1 phase, in
the three different cell lines, compared to free calcitriol
(p < 0.05). The cell cycle arrest in the treated cell lines was not
accompanied by significant changes in the amount of sub-G1
cells (data not shown), relative to the control cells, indicating
little apoptosis after 72 h treatment with free and entrapped
calcitirol. The sub-G1 group represents the apoptotic cells with
fractional DNA, which appear as cells with hypodiploid DNA
content [27]. These data suggest that calcitriol antiproliferative
effects, observed in cytotoxicity assays, could occur in conse-
quence of cell cycle arrest.
Discussion
The antineoplastic activity of calcitriol, the active form of
vitamin D3, has been well documented both in vitro and in vivo.
Despite calcitriol clinical application, it exhibits several limita-
tions. This work addresses the ability of PLGA NPs to over-
come some of the described drawbacks. PLGA nanoparticles
were formulated as promising delivery systems to improve the
therapeutic potential of calcitriol. The PLGA NPs were
prepared by a single emulsion solvent evaporation method and
stabilized with Pluronic®F127. The prepared NPs exhibited
mean diameters smaller than 200 nm and negative zeta poten-
tial. The observed increase in the mean size with the encapsula-
tion of both forms of vitamin, as compared with unloaded NPs,
was anticipated. This effect was reported in studies arguing that
the drug causes an expansion of the polymeric matrix,
increasing the particle size [28]. The decrease in zeta potential
values with the encapsulation of both forms of vitamin could be
attributed to vitamin adsorption on the PLGA NPs surface. As
already reported, the drug adsorbed on the PLGA NP surface
exerts a masking effect of the superficial carboxylic groups,
reducing the effective NP charge [28]. The NP stability is a
result of electrostatic forces due to the PLGA carboxylate
groups at the NP surface, and the surfactant behavior that also
plays a crucial role in maintaining nanosuspension stabilization.
During particle formation, the Pluronic®F127 is adsorbed onto
the NP surface, providing steric and thermodynamic stabiliza-
tion (Figure 1, white arrow) [29].
Both forms of vitamin D3 were used for the formulation of the
nanocarrier system and variations in the encapsulation effi-
ciency and loading capacity were noticed. The observed differ-
ences may be based on their chemical structure, since calcitriol
has two extra hydroxy groups and is less hydrophobic than
cholecalciferol. Thus, its partition into the aqueous phase may
occur during the NP preparation, resulting in lower EE and LC
values [14]. The EE and LC values achieved are in accordance
with our experience with other hydrophobic drugs [30] and
other results reported in literature [20]. The prepared nanoparti-
cles remained stable under storage conditions for several weeks.
The nanoparticle emulsions were successfully lyophilized by
the addition of sucrose to increase the shelf-life time. The
choice of sucrose as the cryoprotective agent was justified by
the previous work of Holzer et al., where it was proven that this
is a well-suited cryoprotectant [31].
PLGA NPs tend to exhibit a biphasic release pattern, character-
ized by an initial rapid release, followed by a slower sustained
release [19]. As expected, the NPs exhibited a rapid release in
the first 24 h due to the release of calcitriol adsorbed onto the
NP surface. The sustained release over the next 168 h could be
attributed to the diffusion of vitamin from the NP core into the
release medium. In aqueous medium, PLGA suffers biodegra-
dation by hydrolytic cleavage of its ester linkages into
monomers. During hydrolysis, acidic degradation products
accumulate inside the PLGA NPs and are responsible for reac-
tion autocatalysis. The hydrolytic breakdown also causes the
formation of pores, allowing the release of oligomers and
monomers, resulting in bulk erosion [32]. As the NP degrad-
ation is slow, the release between 48 and 168 h may depend
mainly on vitamin diffusion through the polymeric matrix and
matrix erosion [19,33].
Human cell lines, S2-013, hTERT-HPNE and A549, were
selected to evaluate the antiproliferative potential of calcitriol-
loaded PLGA NPs. A549 lung carcinoma line proved to be the
least sensitive line to the free calcitriol activity. Pelczynska et
al. previously reported that A549 is a VDR-negative cell line,
only exhibiting VDR expression after incubation with calcitriol,
which explains the low sensitivity to the drug [11]. To this date,
no work regarding calcitriol activity on the pancreatic cell lines,
S2-013 and hTERT-HPNE, was reported. The in vitro prolifera-
tion assay showed that the encapsulation of calcitriol enhanced
its antiproliferative activity. The efficient cell internalization by
an endocytosis mechanism of PLGA NPs and their rapid endo-
lysosomal escape observed in this study could explain the bene-
fits of the drug encapsulation in the NPs. Tahara et al. showed
that PLGA NPs are efficiently internalized by A549 cells by an
endocytosis mechanism, partially mediated by a clathrin [34],
which can explain the NP-enhanced calcitriol activity reported
in this work. Therefore, this mechanism of NP internalization
avoids calcitriol transport out of cells mediated by P-glycopro-
tein involved in the MDR problem. It was previously estab-
lished that after internalization, PLGA NPs suffer a charge
change triggered by the acidic medium of late endosome/lyso-
some. This leads to the destabilization of the endo-lysosomal
membrane, allowing the escape of NPs into the cytoplasm [18].
Also, the prepared nanoparticles were stabilized with the
Pluronic®F127, known for its ability to overcome MDR by
direct inhibition of P-glycoprotein [35]. The obtained results
suggest that these PLGA NPs are able to work as cytoplasmic
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delivery vehicles. Also, because calcitriol has a short half-life,
its entrapment in PLGA NPs allows vitamin protection,
sustained and controlled delivery, thus avoiding drug degrad-
ation and inactivation. The sustained and controlled release of
the prepared PLGA NPs explains the increased inhibition of cell
growth in the 72 h assay, as compared with the 48 h assay. We
conclude that a longstanding treatment presents more
pronounced, deleterious effects since these NPs are able to
maintain drug concentrations.
Furthermore, flow cytometry analysis demonstrated that encap-
sulation of calcitriol in PLGA NPs enhanced the growth inhibi-
tion of the human cells by inhibiting the cell cycle progression
at the G1–S transition, as previously reported [7,12,36,37]. As
confocal imaging studies demonstrated, this cell cycle arrest
was associated with major changes in the morphological
features of the calcitriol-loaded PLGA-NP-treated pancreatic
cells, consistent with the senescence phenomena. Senescent
cells are described as cells permanently arrested in the cell cycle
[38], and it was already reported that calcitriol can trigger cell
senescense [39].
Conclusion
A PLGA NP system was developed for calcitriol delivery. The
prepared system is stable under storage conditions for several
weeks and was lyophilized to increase its shelf life. The NPs
exhibited a rapid release in the first 24 h followed by sustained
release over the following days, after which a diffusion equilib-
rium between the NPs and release medium occurred. The in
vitro cytotoxic studies proved that unloaded PLGA NPs are
biocompatible and revealed the toxicity effect of calcitriol
against human pancreatic and lung cells. Due to the short
calcitriol half-life in the cell culture medium, daily renewal was
necessary to maintain its concentration. This results in an
increase in the frequency of administration, and consequently,
in the increased amount of drug in comparison to calcitriol
encapsulated in the PLGA nanoparticles. As a result, the
obtained data prove that PLGA NPs enhance calcitriol antineo-
plastic activity, allowing reduced administration frequency, as
well as lower drug dosage, and thus increased drug bioavail-
ability. This work also demonstrated that encapsulation in a
nanovehicle enhanced the growth inhibition effect of calcitriol
in the treated human cell lines by inducing cell cycle arrest in
the G1–S phase. This antiproliferative effect was associated
with major morphological changes in the treated cells. The
obtained results suggest that the lack of growth of the human
cells lines upon treatment with free and entrapped calcitriol is a
result of a drug-induced senescence. Thus, we can conclude that
nanoencapsulation in PLGA NPs may offer a new and poten-
tially effective administration strategy of calcitriol that over-
comes the actual limitations such as its low bioavailability.
Experimental
Chemicals
PLGA Resomer® RG503H (50:50; Mw 24,000–38,000), ethyl
acetate, Pluronic®F127, coumarin-6 (C6) (Mw 350.43), phos-
phate buffered saline (PBS), acetic acid, sulforhodamine B
(SRB), trypan blue, ribonuclease A (RNase) from bovine
pancreas (Mw 13,700; solution of 50% glycerol), propidium
iodide (Mw 668.39, purity ≥ 94%) and Triton XTM-100 were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Chole-
calciferol (vitamin D3, Mw 384.65, purity ≥ 99%) was
purchased from Alfa Aesar (Karlsruhe, Germany). Calcitriol
(Rocaltrol, Mw 416.64, purity ≥ 99%) was purchased from
Selleck Chemicals (Munich, Germany). Uranyl acetate (dehy-
drate, 424.146 g/mol) was purchased from Electron Microscopy
Sciences (Hatfield, UK). Dulbecco's Modified Eagle medium
(DMEM) and Roswell Park Memorial Institute medium (RPMI)
were acquired from Invitrogen Co. (Scotland, UK).
Trichloroacetic acid (TCA) and Tris buffer were acquired from
Merck (Darmstadt, Germany). SlowFade® Gold Antifade
Mountant with DAPI and LysoTracker® Deep Red were
purchased from Molecular Probes (Invitrogen Co., Scotland).
Cell lines
Three different human cell lines were used in this work. The
two human pancreatic cell lines, hTERT-HPNE (hTERT
immortalized human pancreatic nestin-expressing normal duct-
derived cells of the human pancreas) and S2-013 (well-differen-
tiated tubular adenocarcinoma and moderately metastatic
subline cloned from the human pancreatic tumor cell line SUIT-
2), were provided by Prof. M. A. Hollingsworth (UNMC,
Nebraska, USA) [40,41]. The human lung cancer cell line,
A549 (nonsmall cell lung carcinoma), [11] was kindly provided
by Dr. Gabriela Almeida (IPATIMUP). For cell culture
purposes, the cell lines were maintained in DMEM (for pancre-
atic cells) or RPMI (for lung cells) medium, supplemented with
10% fetal bovine serum (FBS) at 37 °C in a humidified 5% CO2
incubator. When the cells reached 80% of confluence, they
were trypsinized and subcultured.
PLGA nanoparticle preparation
PLGA NPs were prepared using the single emulsion solvent
evaporation technique. For that purpose, 10 mg of PLGA was
dissolved in 0.1 mL of ethyl acetate, and for encapsulation,
1 mg of vitamin was added. PLGA NPs for the entrapment of
coumarin-6 were also prepared by this method using 1% w/w of
coumarin-6 (C6). 200 μL of an aqueous solution of 1% w/v
Pluronic®F127 was added dropwise to the organic phase. Then,
the solution was vortexed and emulsified by sonication at an
ultrasonic frequency of 45 kHz. The emulsion was subse-
quently poured into 2.5 mL of 0.1% w/v Pluronic®F127 and
stirred (800 rpm) at room temperature until complete evapor-
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ation of the organic solvent. The resulting suspension was
filtered (0.2 μm, Millex-GP Filter Units, Merck Millipore,
Germany) and incubated at 4 °C overnight to increase the NP
stability. Then, the NPs were collected by centrifugation
(14500 rpm, 30 min), and resuspended in ultrapure water. All
formulations were prepared in triplicate.
Calcitriol-loaded PLGA NPs were freeze-dried to avoid the
need to prepare particles whenever we conducted cell studies,
and for the eventual future pharmaceutical applications.
Lyophilization was carried out in a BenchTopTM K series
freeze-dryer (VirTis, NY, USA) at 5 × 10−5 bar and −95 °C for
48 h.
PLGA nanoparticle physicochemical
characterization
The size, polydispersity index (PDI), zeta potential,
morphology, vitamin loading capacity and encapsulation effi-
ciency were the parameters used to characterize the produced
nanoparticles. The size distribution and zeta potential were
determined by dynamic light scattering (DLS) and elec-
trophoretic light scattering (ELS), respectively, using a Zeta-
Sizer Nano ZS (Malvern Instruments, Worcestershire, UK). The
size distribution was given by the PDI. DLS and ELS measure-
ments were also performed to evaluate modifications in the
PLGA NP size and zeta potential and possible particle aggrega-
tion over time under storage conditions (aqueous suspension
stored at 4 °C) and after freeze-drying. The effect of sucrose (at
a concentration of 1% w/v) used as a cryoprotective agent on
the NPs stability during freeze-drying was also determined. The
stability of the calcitriol in the NPs was evaluated by UV–vis
spectrophotometry measurements after freeze-drying.
Unloaded and vitamin-loaded PLGA NPs were also analyzed
for size and morphology by transmission electron microscopy
(TEM) using a JEOL JEM 1400 microscope (Tokyo, Japan) at
an accelerating voltage of 80 kV. The samples were deposited
on copper grids (formvar/carbon on 400 mesh Cu from Agar
Scientific) and negative-stained with 2% v/v uranyl acetate for
45 s. The grids were air-dried prior to TEM visualization [42].
Vitamin loading capacity (LC) and the encapsulation efficiency
(EE) of PLGA NPs were further indirectly determined. For the
quantification of the free vitamin, the NP suspension was
centrifuged (14500 rpm, 30 min), and the supernatant analyzed.
This step was conducted before organic solvent evaporation to
ensure vitamin solubility. The sample was measured by UV–vis
spectrophotometry at 265 nm, using a UV-1700 PharmaSpec
UV–vis spectrophotometer from Shimadzu (Japan). The results
were inferred from a calibration curve of known vitamin
concentrations. All experiments were performed in triplicate.
In vitro release studies
The in vitro release behavior of calcitriol entrapped in PLGA
NPs was assessed over seven days. A sufficient amount of
calcitriol-loaded PLGA NPs were resuspended in release buffer
(PBS 0.01 M, pH 7.4) and divided into 7 aliquots. The aliquots
were maintained at 37 °C and at determined set time points, and
each aliquot was centrifuged at 14500 rpm for 30 min.
Amicon® Ultra-0.5 centrifugal filter devices (Merck Millipore,
Germany) were used to remove PLGA degradation
products and NPs. The release medium was freeze-dried
and further reconstituted with ethanol 100% v/v for measure-
ment by UV–vis spectrophotometry at 265 nm and the
amount of released calcitriol was calculated from the calibra-
tion curve in ethanol. A solution of calcitriol in PBS was used
as control to assess the stability of calcitriol in the release
conditions over the seven days. All experiments were per-
formed in triplicate.
Cellular imaging studies
Laser scanning confocal microscopy (LSCM) was used to eval-
uate the NP in vitro uptake and morphological changes in
S2-013, hTERT-HPNE and A549 cells. The cells were seeded
in µ-chamber 12-well plates (ibidi, Germany) at a density of
1000 cells per well for 24 h prior to the experiment. This period,
under normal conditions (5% CO2 humidified atmosphere at
37 °C), allows cells to adhere. The cells were then treated with
2.4 µM free calcitriol and entrapped calcitriol in C6-loaded
PLGA NPs for 2 and 72 h. The lipophilic fluorescent dye C6
entrapped in the NP matrix does not leach during the experi-
ment, allowing a fluorescent visualization of the uptake of
PLGA NPs [30]. After the incubation period, the cells were
rinsed with PBS and fixed using 4% paraformaldehyde for
15 min. The cells were then treated with LysoTracker® Red (a
marker of endo-lysosomal compartments) for 1 h. The cells
were washed with PBS and mounted on a glycerol-based
medium with DAPI for nuclear staining. Acquisitions were per-
formed with a Leica TCS SP5 II confocal laser scanning micro-
scope (Leica Microsystems, Germany) in emission mode.
Untreated cells were also imaged as control. Different areas
were analyzed and at least six images were acquired for each
type of cell. The ImageJ JACoP “colocalization finder” plug-in
was used for the determination of the Pearson coefficient (r), as
a quantitative indicator of colocalization of the NPs in the lyso-
somes of cells.
In vitro cytotoxicity studies
The effects of the calcitriol-loaded PLGA nanoparticles and free
calcitriol on the cell growth of different human cell lines were
evaluated by sulforhodamine B (SRB). This colorimetric
method allows an indirect estimation of cell number by
measuring cellular protein content [43].
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The experiments were performed in 96-well assay plates, where
exponentially growing cells were seeded for an incubation
period of 24 h at a density of 1000 cells per well before treat-
ment with free calcitriol, blank PLGA NPs and calcitriol-loaded
PLGA NPs. The NP samples and free calcitriol were diluted in
cell culture medium at eight final concentrations of calcitriol
ranging from 0.005 to 3.2 µM, and the cells were incubated
with these samples for 48 h and 72 h. A calcitriol stock solution
of 3.2 mM was prepared in ethanol to ensure calcitriol solu-
bility, but all samples of calcitriol alone contained at most
0.1% v/v ethanol. Due to the short half-life of calcitriol in cell
culture medium, the supplemented medium was renewed daily
[44]. After the 48–72 h incubation period, the cytotoxic effect
was assayed by SRB, in a similar manner as previously
described in [30]. The cells were fixed with 10% TCA for 1 h at
4 °C. The cell monolayers were then washed and stained with
50 µL SRB dye for 30 min. The cells were subsequently
washed repeatedly with 1% acetic acid to remove any unbound
dye. The cells were air-dried and the protein-bound stain was
solubilized with 10 mM Tris solution. The SRB absorbance was
measured at 560 nm using the PowerWave microplate reader
(HT Microplate Spectrophotometer, BioTek). By comparing the
measured absorbance of the wells containing the drug or the
NPs with the measurements of the wells containing the
untreated cells, it was possible to generate dose-response
profiles and determine the concentration inhibiting the net cell
growth by 50% (GI50). This step was perfomed following the
incubation period, and subsequent comparison of these results
with those obtained for cells that had been fixed at time zero
(the time at which calcitriol/NPs were added).
Unloaded PLGA NPs and 0.1% of ethanol were added as a
control to assess the effect on cell growth in control cells. Unex-
posed cells were also included in all assays as nontreatment
controls (null controls). Two independent experiments were
measured in triplicate.
Cell cycle analysis
The cell cycle analysis was conducted by flow cytometry
(FCM). The cells were seeded in T75 flasks at a density of
1 × 105 cells/mL for 24 h prior to the experiment. The cells
were then treated with 1.2 µM of free calcitriol and entrapped in
PLGA NPs for 72 h. Due to the short half-life of calcitriol in
cell culture medium, the supplemented medium with free
calcitriol was renewed daily. Untreated cells were also used as a
control. To reduce the effects of contact inhibition, control cells
were adjusted to reach 60–70% confluence at the time of FCM
analysis. After the incubation period, the cells were harvested
and fixed with 70% v/v ethanol. The cells were then stained
with a DNA staining solution (0.1% v/v TritonX-100,
20 µg/mL PI and 35 µg/mL of RNase A in PBS) at a cell
density of 106 cells/mL. FCM (FACSCalibur, BD Biosciences,
CA, USA) was performed by plotting 12,000 gated events per
sample. The data were subsequently analyzed by FlowJo 7.2
software (Tree Star, Ashland, USA). Three independent experi-
ments were conducted.
Statistical analysis
Statistical analysis was performed by using a two-tailed
Student’s t-test, considering a 95% confidence interval.
p-values lower than 0.05 were considered significant.
Acronyms
Table 4: List of abbreviations used within the article.
Term Abbreviation
drug delivery systems DDS
dynamic light scattering DLS
Dulbecco's Modified Eagle mMedium DMEM
encapsulation efficiency EE
electrophoretic light scattering ELS
enhanced permeability and retention effect EPR effect
fetal bovine serum FBS
flow cytometry FCM
Food and Drug Administration FDA
half maximal growth inhibitory concentration GI50
half maximal survival inhibitory concentration IC50
loading capacity LC
laser scanning confocal microscopy LSCM
multidrug resistance MDR
nanoparticles NPs
phosphate buffered saline PBS
polydispersity index PDI
poly(glycolic acid) PGA
propidium iodide PI
poly(lactic acid) PLA
poly(lactic-co-glycolic acid) PLGA
Roswell Park Memorial Institute medium RPMI
sulforhodamine B SRB
trichloroacetic acid TCA
transmission electron microscopy TEM
ultraviolet–visible radiation UV–vis
vitamin D receptor VDR
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